Genetic Predictors of Renal Dysfunction Following Heart Transplantation
Pharmacogenomics of Calcineurin Inhibitor Nephrotoxicity in Cardiac Transplantation
4 other identifiers
observational
300
1 country
1
Brief Summary
Kidney disease is a common problem after heart transplantation. It may be caused by anti-rejection medications such as cyclosporine or tacrolimus. However, the reason why some people develop kidney problems after a heart transplant, but other people do not, is not fully known. This study plans to learn more about the relationship between a person's genetic make-up (DNA; deoxyribonucleic acid) and the risk of kidney problems after a heart transplant. The long-term goal of this research is to identify genetic variations that may help predict the development of kidney problems after heart transplantation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2012
CompletedFirst Submitted
Initial submission to the registry
September 12, 2012
CompletedFirst Posted
Study publicly available on registry
September 17, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedMay 10, 2023
May 1, 2023
13.3 years
September 12, 2012
May 9, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Chronic renal dysfunction
year 2 post-transplant
Study Arms (1)
Cardiac transplant recipients
Eligibility Criteria
Cardiac transplant clinic
You may qualify if:
- cardiac-only transplant
- years of age or older at the time of cardiac transplant
- year or more post-cardiac transplant
- treatment with cyclosporine or tacrolimus following transplant
You may not qualify if:
- combined organ transplant
- decisionally impaired
- unable to read or speak English
- unable or unwilling to provide written informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Colorado, Denverlead
- National Jewish Healthcollaborator
Study Sites (1)
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
Biospecimen
Buccal cell and blood sample for genomic DNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christina L Aquilante, Pharm.D.
University of Colorado, Denver
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 12, 2012
First Posted
September 17, 2012
Study Start
August 1, 2012
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
May 10, 2023
Record last verified: 2023-05